


Percutaneous Approaches to Periprosthetic Regurgitation

**Charanjit S. Rihal MD MBA
Professor of Medicine
Director, Cardiac
Catheterization Laboratory**

**Mayo Clinic and Foundation
Rochester, MN, USA**



DISCLOSURES


Relevant Financial Relationship(s)

None

Off Label Usage

AGA

Percutaneous Approaches to Periprosthetic Regurgitation



5 - 17% of valves
Hemolysis, CHF
Difficult to treat
Underestimated

60 yo Man

- **AVR 1981 – endocarditis**
- **Starr-Edwards AVR + MVR 1989 due to endocarditis.**
- **CHF class IV. AF. ICD.**
- **Severe LV dysfunction EF 10%**
- **Severe periprosthetic leak**



11:08:32 am



TE-V5M 48Hz

5.0MHz 180mm

MAYO TEE

General /V

Lens Temp=38.1°C



65dB S1/ 0/1/6

Gain= 20dB Δ=1

Store in progress

HR= 75bpm






11:29:46 am
 TE-V5M 15Hz
 5.0MHz 140mm
 MAYO TEE
 General /V
 Lens Temp=37.7°C



T1/-2/ 0/V:A
 1/2 **CD:3.5MHz**
 CD Gain = 54

Store in progress
 HR= 67bpm






Severe Periprosthetic Mitral Regurgitation with 7mm Orifice




46 55dB 3 +/-1/1/2
CW Focus= 74mm
CW Gain= 4dB



CW:3.5MHz




$\Delta \bar{V} = 1.37\text{m/s}$
Dist = 0.71cm





Deflectable Transseptal Guiding Catheter


Extra Support Guide Wire






Deployment Guiding Catheter Through Defect





**Deployment
Guiding Catheter
Through Defect
Medial Aspect**





Post Deployment





11:40:47 am
 TE-V5M 23Hz
 5.0MHz **317mm**
 MAYO TEE
 General /V
 Lens Temp=37.7°C

T1/-2/ 0/V:A
 1/2 **CD:3.5MHz**
 CD Gain = 51





Store in progress
 HR=201bpm







60 yo Man



- **Immediate improvement**
- **Murmur gone**
- **Significant functional improvement**
- **Still alive**

Techniques, Devices, Examples







Multiple Defects




Multiple defects



Post closure





Necessity is the Mother of Invention ***- Plato, The Republic***




Anatomic Considerations









Periprosthetic Leaks

- **Most common cause of nonstructural prosthetic valve failure**
- **Clinically significant leaks can present any time after surgery with**
 - 1. decompensated heart failure,**
 - 2. hemolytic anemia or**
 - 3. endocarditis**

Etiology of Periprosthetic Regurgitation

- 1. Tissue friability**
- 2. Extensive annular calcification**
- 3. Dehiscence of prosthesis**
- 4. Type of prosthesis
(mechanical more likely?)**
- 5. Posteromedial and anteromedial annulus**

Successful Percutaneous Repair of Perivalvular Prosthetic Regurgitation

Paul Sorajja,¹ MD, Allison K. Cabalka,² MD, Donald J. Hagler,² MD, Guy S. Reeder,¹ MD, Krishnawamy Chandrasekaran,¹ MD, Frank Cetta,² MD, and Charanjit S. Rihal,^{1*} MD

Objective: To examine the feasibility and outcome of percutaneous transcatheter repair of perivalvular regurgitation. **Background:** Perivalvular prosthetic regurgitation causes significant morbidity, and is associated with high perioperative mortality if open surgical repair is required. **Methods:** Percutaneous repair of perivalvular regurgitation was attempted in 16 patients with heart failure or hemolytic anemia. All patients were either not candidates or were high-risk for open surgical repair (Parsonnet score, 39 ± 7). Regurgitant lesions were perimitral in 14 patients (2 had multiple defects) and peri-aortic in 2 patients. Under echocardiographic and fluoroscopic guidance, patients underwent implantation of either the Amplatzer Septal Occluder or Duct Occluder. **Results:** Successful percutaneous closure with mild or no residual regurgitation was achieved in 17 of 21 attempts (81%). In one patient, an occluder could not be deployed. There were no procedural deaths, strokes, or myocardial infarctions, and no prosthetic obstruction from device deployment. NYHA functional class improved from 3.1 ± 0.6 to 2.0 ± 1.0 at follow-up (mean, 3.1 mos; $P = 0.0001$ vs. baseline). One patient with heart failure had symptom resolution but died suddenly 4 weeks after the procedure. One subsequent noncardiac death and two late deaths from progressive heart failure also occurred. **Conclusions:** Percutaneous repair of perivalvular prosthetic regurgitation is a feasible alternative to open surgical correction, and may be preferred in patients at significant perioperative risk. Further experience with careful attention to patient selection, late morbidity, and mortality is required in this high risk patient subset. © 2007

Wiley-Liss, Inc.

Percutaneous Periprosthetic Regurgitation Repair

- 37 procedures in 34 patients.
- Symptoms: HF 20, hemolysis 1, both 13
- 22 males, median age 66
- perimitral 27, periaortic 7

Percutaneous Periprosthetic Regurgitation Repair

- **Successful closure 32 of 37 procedures**
- **No death, MI, stroke, or device embolization**
- **Failure to deploy n=2**
- **Valve interference n=2**
- **Defect too large 1**

Percutaneous Periprosthetic Regurgitation Repair

- 2 ongoing hemolysis referred to surgery
- 1 sudden death
- 3 deaths from HF
- 1 noncardiac death

Functional Improvement



PRINCIPLES

- **Comprehensive imaging**
- **Risk of alternatives**
- **Exclude infection**
- **Multidisciplinary approach**
- **Comfort with wide variety of techniques**



MAYO CLINIC